GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection.
Frago. Laura M LM; Pañeda. Covadonga C; Dickson. Suzanne L SL; Hewson. Adrian K AK; Argente. Jesús J; Chowen. Julie A JA
Key Findings
- GHRP‑6 (and GH) increased IGF‑I mRNA in the hypothalamus, cerebellum, and hippocampus but not in the cortex.
- Activation of the Akt/Bad survival pathway and higher levels of the anti‑apoptotic protein Bcl‑2 were observed where IGF‑I rose.
- IGFBP‑5, another protein linked to neuron survival, was elevated mainly in the hypothalamus.
Practical Outcomes
- The study hints that GHRP‑6 could enhance brain IGF‑I signaling and neuroprotective pathways, which may translate to benefits for memory, mood, or brain health. However, the data are from rats, so human effects, optimal doses, and safety are still unknown. Biohackers should treat this as preliminary evidence and await human trials before incorporating GHRP‑6 specifically for brain benefits.
Summary
In rats, giving GH or the peptide GHRP‑6 for a week raised the brain's own IGF‑I production in key memory and hormone centers, turned on cell‑survival signals, and boosted protective proteins, suggesting a possible brain‑protective effect.
Abstract
Beneficial effects of GH on memory, mental alertness, and motivation have been documented. Many actions of GH are mediated through IGF-I; hence, we investigated whether systemic administration of GH or GH-releasing peptide (GHRP)-6 modulates the brain IGF system. Treatment of adult male rats with GHRP-6 or GH for 1 wk significantly increased IGF-I mRNA levels in the hypothalamus, cerebellum, and hippocampus, with no effect in cerebral cortex. Expression of the IGF receptor and IGF-binding protein (IGFBP)-2 were not affected. Phosphorylation of Akt and Bad was stimulated in areas where IGF-I was increased, with no change in MAPK or glycogen synthase kinase-3beta. This suggests that GH and GHRP-6 activate phosphatidylinositol kinase intracellular pathways involved in cell survival in response to growth factors. Indeed, the antiapoptotic protein Bcl-2 was augmented in these same areas, with no change in the proapoptotic protein Bax. IGFBP-5, also reported to be involved in neuron survival processes, was increased mainly in the hypothalamus, suggesting a possible neuroendocrine role. In conclusion, GH and GHRP-6 modulate IGF-I expression in the central nervous system in an anatomically specific manner. This is coincident with activation of intracellular signaling pathways used by IGF-I and increased expression of proteins involved in cell survival or neuroprotection.
Study Information
pubmed
2002
10.1210/en.2002-220261